ADPT
Adaptive Biotechnologies CorpNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.17B
P/E Ratio
—
EPS
$-0.39
Beta
2.30
52W High
$20.76
52W Low
$6.78
50-Day MA
$15.49
200-Day MA
$14.65
Dividend Yield
—
Profit Margin
-21.50%
Forward P/E
—
PEG Ratio
0.00
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company is headquartered in Seattle, Washington.
Fundamentals
| Revenue (TTM) | $276.98M |
| Gross Profit (TTM) | $205.62M |
| EBITDA | $-39.29M |
| Operating Margin | -17.80% |
| Return on Equity | -27.80% |
| Return on Assets | -6.79% |
| Revenue/Share (TTM) | $1.83 |
| Book Value | $1.42 |
| Price-to-Book | 10.43 |
| Price-to-Sales (TTM) | 7.83 |
| EV/Revenue | 7.71 |
| EV/EBITDA | -1.00 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 51.00% |
| Shares Outstanding | $153.98M |
| Float | $118.52M |
| % Insiders | 2.03% |
| % Institutions | 100.87% |
Analyst Ratings
Consensus ($20.86 target)
2
Strong Buy5
Buy1
HoldData last updated: 4/7/2026